Humana Boosts Outlook on Lower-Than-Expected Medicare Advantage Membership Drop

Humana (HUM) significantly raised its full-year adjusted EPS outlook to $17.00 from $16.25 and revenue guidance to at least $128 billion, driven by a smaller anticipated decline in Medicare Advantage membership and stronger patient growth at its CenterWell Primary Care centers. The health insurer also reported second-quarter adjusted EPS of $6.27 and revenue of $32.39 billion, both exceeding analyst expectations, attributing the outperformance to CenterWell's strong results and better-than-expected Medicare Advantage enrollment, which sent shares up 5%.

Analysis

Humana (HUM) has issued a significant upward revision to its full-year guidance, signaling improving fundamentals in its core business segments. The company raised its adjusted EPS forecast to approximately $17.00 from $16.25 and its revenue outlook to at least $128 billion. This optimism is underpinned by two key operational developments: a smaller-than-anticipated decline in Medicare Advantage membership, now projected at 500,000 versus a prior estimate of 550,000, and a substantial increase in expected net patient growth at its CenterWell Primary Care centers to a range of 50,000-70,000, up from 30,000-50,000. The guidance lift is supported by a strong second-quarter performance, where the company exceeded analyst estimates with an adjusted EPS of $6.27 and a nearly 10% year-over-year revenue increase to $32.39 billion. This outperformance was attributed to strong results at CenterWell and better-than-expected Medicare Advantage enrollment. Despite a 5% share price increase on this news, the stock remains slightly down year-to-date, suggesting the market is just beginning to price in this recovery narrative.

Key Decisions for Investors

• The upward revisions to both Medicare Advantage membership and CenterWell patient growth provide fundamental justification for re-evaluating underweight positions, as these core drivers signal a strengthened operational outlook.
• Investors should monitor upcoming quarters to confirm that the revised Medicare Advantage membership decline holds and that CenterWell achieves its new, higher patient growth targets, as these metrics are now central to the company's valuation thesis.
• Given that the stock remains negative year-to-date despite a 5% rally on the news, the current valuation may present a strategic entry point for investors who believe the positive guidance reflects a durable operational turnaround.